Get the Stockscreener App
4.7596
1.94%
0.1096
Fennec Pharmaceuticals Inc stock is traded at $4.7596, with a volume of 52,521.
It is up +1.94% in the last 24 hours and up +2.60% over the past month.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
See More
Previous Close:
$4.65
Open:
$4.62
24h Volume:
52,521
Relative Volume:
0.62
Market Cap:
$127.24M
Revenue:
$21.25M
Net Income/Loss:
$-16.05M
P/E Ratio:
-4.7596
EPS:
-1
Net Cash Flow:
$-17.14M
1W Performance:
-1.04%
1M Performance:
+2.60%
6M Performance:
-48.65%
1Y Performance:
-31.30%
1-Day Range:
$4.62
$4.9999
1-Week Range:
$4.26
$4.9999
52-Week Range:
$4.09
$11.92
Fennec Pharmaceuticals Inc Stock (FENC) Company Profile
Name
Fennec Pharmaceuticals Inc
Sector
Industry
Phone
(919) 636-4530
Address
PO BOX 13628, RESEARCH TRIANGLE PARK, NC
Fennec Pharmaceuticals Inc Stock (FENC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-22-22 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Sep-07-22 | Initiated | CapitalOne | Overweight |
| Aug-08-22 | Resumed | Craig Hallum | Buy |
| Jun-05-20 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-11-18 | Initiated | Goldman | Buy |
Fennec Pharmaceuticals Inc Stock (FENC) Latest News
Insider Selling: Fennec Pharmaceuticals Inc (NASDAQ:FENC) Director Sells 2,431 Shares of Stock - MarketBeat
Fennec Pharmaceuticals director Raykov Rosty sells $10,477 in stock By Investing.com - Investing.com Australia
Fennec Pharmaceuticals director Raykov Rosty sells $10,477 in stock - Investing.com
Fennec Pharmaceuticals (FENC) to Release Earnings on Thursday - MarketBeat
Fennec Pharmaceuticals (FRX) Set to Announce Quarterly Earnings on Thursday - MarketBeat
Fennec Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 7, 2024 - ForexTV.com
RTP drugmaker appoints new execs following CEO swap - The Business Journals
Fennec Pharmaceuticals Strengthens Leadership Team for Growth - TipRanks
Individual investors account for 31% of Fennec Pharmaceuticals Inc.'s (NASDAQ:FENC) ownership, while hedge funds account for 30% - Yahoo Finance
Fennec Pharmaceuticals (TSE:FRX) Stock Price Passes Below 50 Day Moving AverageWhat's Next? - MarketBeat
Eupraxia Pharmaceuticals Inc. - Baystreet.ca
Fennec Pharmaceuticals expands leadership team - The Pharma Letter
Fennec Pharmaceuticals Inc. - Baystreet.ca
Fennec Pharmaceuticals Strengthens Executive Leadership Team with Three Key Appointments to Accelerate the Company's Next Stage of Growth - The Manila Times
Fennec Pharmaceuticals Strengthens Executive Leadership Team with Three Key Appointments to Accelerate the Company’s Next Stage of Growth - ForexTV.com
Q3 EPS Estimates for FENC Boosted by Capital One Financial - Defense World
Capital One Financial Estimates TSE:FRX Q3 Earnings - MarketBeat
Financial Comparison: Kodiak Sciences (NASDAQ:KOD) & Fennec Pharmaceuticals (NASDAQ:FENC) - Defense World
Fennec Pharma stock hits 52-week low at $4.11 amid market challenges - Investing.com India
Fennec Pharmaceuticals director sells shares worth over $6,000 By Investing.com - Investing.com South Africa
Fennec Pharma stock hits 52-week low at $4.11 amid market challenges By Investing.com - Investing.com South Africa
Fennec Pharmaceuticals director sells shares worth over $6,000 - Investing.com
Fennec Pharmaceuticals (TSE:FRX) Reaches New 12-Month LowTime to Sell? - MarketBeat
Fennec: Operational Challenges Persist Despite Improved Financial Position (NASDAQ:FENC) - Seeking Alpha
Rostislav Christov Raykov Sells 2,431 Shares of Fennec Pharmaceuticals Inc. (TSE:FRX) Stock - Defense World
Revenues Working Against Fennec Pharmaceuticals Inc.'s (NASDAQ:FENC) Share Price - Simply Wall St
Fennec Pharma stock hits 52-week low at $4.57 amid market challenges - Investing.com
Fennec Pharmaceuticals director sells over $12k in company stock - Investing.com India
Norgine Announces Appointment of New CEO Janneke van der Kamp - PR Newswire UK
Insider Sale: Director Rosty Raykov Sells Shares of Fennec Pharm - GuruFocus.com
Fennec Pharmaceuticals Inc (NASDAQ:FENC) Director Sells $12,009.14 in Stock - Defense World
The past three years for Fennec Pharmaceuticals (NASDAQ:FENC) investors has not been profitable - Yahoo Finance
Fennec Pharmaceuticals (TSE:FRX) Reaches New 1-Year Low at $6.60 - Defense World
Fennec Pharmaceuticals Inc (NASDAQ:FENC) Stock Holdings Increased by Bank of New York Mellon Corp - Defense World
Fennec Pharma stock hits 52-week low at $4.96 amid challenges - Investing.com
Fennec Pharmaceuticals (TSE:FRX) Reaches New 12-Month Low at $7.00 - Defense World
Fennec Pharmaceuticals (NASDAQ:FENC) & Inhibikase Therapeutics (NYSE:IKT) Head to Head Review - Defense World
Acadian Asset Management LLC Makes New Investment in Fennec Pharmaceuticals Inc (NASDAQ:FENC) - Defense World
(FENC) Long Term Investment Analysis - Stock Traders Daily
WINTON GROUP Ltd Buys Shares of 67,005 Fennec Pharmaceuticals Inc (NASDAQ:FENC) - Defense World
Fennec Pharmaceuticals (NASDAQ:FENC) Stock Price Down 4.9% - MarketBeat
Fennec Pharmaceuticals Inc. (TSE:FRX) Director Sells C$18,115.81 in Stock - Defense World
Fennec Pharmaceuticals (TSE:FRX) Hits New 1-Year Low at $7.00 - MarketBeat
Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences - Kincardine News
Fennec Pharmaceuticals director sells shares worth over $13k - Investing.com
Fennec Pharmaceuticals director sells shares worth over $13k By Investing.com - Investing.com UK
Fennec Pharmaceuticals (TSE:FRX) Shares Cross Below Fifty Day Moving Average of $8.25 - MarketBeat
Fennec Pharmaceuticals Inc Forecasted to Post FY2024 Earnings of ($0.21) Per Share (NASDAQ:FENC) - MarketBeat
Research Analysts Set Expectations for Fennec Pharmaceuticals Inc’s FY2024 Earnings (NASDAQ:FENC) - Defense World
Cantor Fitzgerald Weighs in on Fennec Pharmaceuticals Inc.’s FY2024 Earnings (TSE:FRX) - Defense World
(FENC) Trading Advice - Stock Traders Daily
Fennec Pharmaceuticals Inc Stock (FENC) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):